Shanghai – October 12, 2026 -- Shanghai Ark Biopharmaceutical (ArkBio) has received U.S. Food and Drug Administration clearance of its investigational new drug application for AK0406, allowing a phase II trial of the long-acting antiviral drug-Fc conjugate for influenza prevention in the general U.S. population.